Bio Products Laboratory (BPL), a specialist manufacturer of plasma-derived medicinal products, announces that it will be investing £23m to build a new Sterile Filling Suite at its Elstree site in the UK. From its base in Hertfordshire, BPL fractionates plasma to manufacture therapeutic products which are then supplied to patients in more than 45 countries around the world.
This expansion of BPL’s filling capacity supports the increasing global needs for plasma-derived medicinal products. It will also provide capacity to manufacture upcoming new products which are currently in development at BPL. The 1,000m2 state-of-the-art suite will be built within an extended and re-purposed area.
The construction is planned to commence in 2021, with the new facility becoming operational by the end of 2023.
We are delighted to announce this investment, which further contributes to our long-term growth strategy and adds to our capabilities as a global supplier from our base here in the UK. We look forward to the benefits that this investment will bring to our patients and to the wider benefits that this investment brings to our employees, our community and our business.
Chief Operations Officer, BPL Therapeutics
About Bio Products Laboratory (BPL)
Recognising the importance of plasma and with many years of experience in the industry, BPL supplies high quality plasma derived medicines to meet the needs of clinicians, patients and customers globally. Headquartered in the United Kingdom and with plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com.